Introduction
HCQ is a disease-modifying drug used in the treatment of various rheumatological and dermatological conditions. In spite of its improved safety profile compared with its predecessor, chloroquine, it is now becoming clearer that retinal toxicity is a side effect of prolonged use and is emerging as a significant cause of visual loss for susceptible patients on this therapy.
Retinopathy caused by antimalarials, first described in 1963, 1 is usually asymptomatic, and by the time symptoms of photosensitivity and patchy visual loss develop, retinal changes are already present. The introduction of more sophisticated imaging has enabled the identification of pre-symptomatic retinal changes indicative of toxicity. 2, 3 Case 1
A 63-year-old caucasian female presented with glare and decreased vision for 9 months having taken HCQ 400 mg per day for RA for 16 years (cumulative dose of 2336 g; 4.93 mg/kg per day). Her medications included omeprazole, methotrexate, and folic acid. Her renal function was 84 ml/min/1.73 m 2 . Visual acuities were 6/6 right and 6/7.4 left. Fundoscopy and imaging revealed subtle disturbances of the macular retinal pigment epithelium, increased AF signal on Scanning Laser Ophthalmoscopy (SLO), with bilateral parafoveal thinning on Spectral Domain OCT imaging (Figures 1a  and b, Figures 2a and b) . 4 Ring scotomata were identified on visual field testing ( Figures 3a  and b) ; electrophysiology demonstrated normal rod and cone responses, but abnormal macular function. Repeat testing 6 months later revealed stable visual acuities and no deterioration on electrophysiological testing. . Visual acuities were 6/6 in both eyes. Imaging and functional testing confirmed a central maculopathy (Figures 1e  and f, Figures 2e and f, Figures 3e and f) .
Discussion
HCQ is a widely used drug found to be of significant benefit in rheumatological and dermatological conditions, with demonstrated survival benefits for SLE. 5 However, like Chloroquine, where a similar bull's eye maculopathy develops, HCQ has now also been shown to be associated with significant retinal toxicity in susceptible individuals. While older studies have estimated HCQ toxicity to be infrequent at~0.5-1% of those taking HCQ for greater than 5 years, 6 recent epidemiological data indicate that retinal toxicity occurs in greater than 10% of patients, who have taken HCQ for over 10 years, and 20-50% of patients taking HCQ for greater than 20 years. 7 The 2009 Royal College of Ophthalmologists Guidelines on HCQ screening advise referral to an Ophthalmologist only if the patient has baseline visual impairment, eye disease confirmed by an optometrist, or if the patient notices visual symptoms. 8 This was based on the premise that the introduction of HCQ was a safe option and was not thought to be associated with the same toxicity as chloroquine. Patients were previously instructed to selfmonitor with an Amsler grid, but regular screening has not been common practice in the UK. 
Eye
The American Academy of Ophthalmology (AAO) 2016 guidelines recommend baseline ophthalmologic examination including fundoscopy with further testing if abnormalities are present at baseline, as well as annual automated central visual field testing (Humphrey 10-2), SD-OCT, and AF after 5 years of exposure or sooner. 3 Amsler grid monitoring was not included in the recommendations because it was regarded as subjective and unreliable.
It is now clear that visual acuities, 10-2 visual fields, and imaging with OCT and FAF and if indicated, multifocal ERG, should be used to look for presymptomatic retinal toxicity. 3, 7 Some patients' retinopathy progresses despite stopping treatment; involvement of the external limiting membrane on OCT carries negative prognostic value, suggestive of irreversible photoreceptor damage. 9 We review the specific retinal imaging and functional testing features in more detail in the accompanying review. 10 Asian patients demonstrate a pericentral pattern of disease, and wider field imaging and visual field testing (30-2) may be required in these patients. 11, 12 Rheumatologists, Ophthalmologists and General practitioners who are involved in the care of these patients need to be aware of the need for initial screening and regular monitoring of patients. These cases highlight the importance of recognising and managing this emerging problem. Instituting a standardised screening protocol would enable cessation of therapy as early as possible, thus reducing the risk and extent of retinal toxicity. In the accompanying review, 10 we present a proposal for screening and monitoring, which includes practical suggestions for imaging and functional testing.
